Cardiac arrhythmias in congestive heart failure

References

• Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation119(14), e391–e479 (2009).
   PubMed Web of Science ®Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J.29, 2388–2442 (2008).
   PubMed Web of Science ®Google Scholar
• Roger VL, Weston SA, Redfield MM et al. Trends in heart failure incidence and survival in a community-based population. JAMA21, 292(3), 344–350 (2004).
   Google Scholar
• Schocken DD, Benjamin EJ, Fonarow GC et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation117, 2544–2565 (2008).
   PubMed Web of Science ®Google Scholar
• Francis GS. Development of arrhythmias in the patients with congestive heart failure: pathophysiology, prevalence and prognosis. Am. J. Cardiol.57, 3B–7B (1986).
   PubMed Web of Science ®Google Scholar
• Podrid PJ, Fogel RI, Fuchs TT. Ventricular arrhythmia in congestive heart failure. Am. J. Cardiol.69, 82G–96G (1992).
   Web of Science ®Google Scholar
• Singh SN, Fisher SG, Carson PE, Fletcher RD; Department of Veterans Affairs CHF STAT Investigators. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. J. Am. Col. Cardiol.32, 942–947 (1998).
   PubMed Web of Science ®Google Scholar
• Cleland JGF, Swedberg K, Follath F et al.; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur. Heart J.24, 442–463 (2003).
   PubMed Web of Science ®Google Scholar
• Rivero-Ayerza M, Reimer WS, Lenzen M et al. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. Eur. Heart J.29, 1618–1624 (2008).
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Levy D, Vaziri SM et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA271, 840–844 (1994).
   PubMed Web of Science ®Google Scholar
• Sartiani L, Stillitano F, Cerbai E, Mugelli A. Electrophysioilogic changes in heart failure: focus on pacemaker channels. Can. J. Physiol. Pharmacol.87, 84–90 (2009).
   PubMed Web of Science ®Google Scholar
• Weiss JN, Qu Z. Molecular and cellular basis of arrhythmias in heart failure. In: Atlas of Electrophysiology in Heart Failure. Shivkumar K, Wesis JN, Fonarow GC, Naula J, Braunwald E (Eds). Current Medicine LLC, PA, USA (2005).
   Google Scholar
• Yano M. Ryanodine receptor as a new therapeutic target of heart failure and lethal arrhythmia. Circ. J.72, 509–514 (2008).
   PubMed Web of Science ®Google Scholar
• Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ. Res.95, 754–763 (2004).
   PubMed Web of Science ®Google Scholar
• Frenneaux MP. Autonomic changes in patients with heart failure and in post-myocardial infarction patients. Heart90, 1248–1255 (2004).
   PubMed Web of Science ®Google Scholar
• Makkar KM, Sanoski CA, Spinlen SA. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonist in the prevention of atrial and ventricular arrhythmias. Pharmacotherapy29(1), 31–48 (2009).
   PubMed Web of Science ®Google Scholar
• Wanwarang W, Chen SA. Management of atrial fibrillation in patients with heart failure; from drug therapy to ablation. Expert Rev. Cardiovasc. Ther.7(3), 311–322 (2009).
   PubMedGoogle Scholar
• Patel D, Natale A, Di Biase L et al. Catheter ablation for atrial fibrillation: a promising therapy for congestive heart failure. Expert Rev. Cardiovasc. Ther.7(7), 779–787 (2009).
   PubMedGoogle Scholar
• Nayar V, Pugh PJ. Cardiac resynchronization therapy for the treatment of heart failure. Expert Rev. Cardiovasc. Ther.8(2), 229–239 (2010).
   PubMedGoogle Scholar
• Torp-Pedersen C, Møller M, Block-Thomsen PE et al.; The Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N. Engl. J. Med.341, 857–865 (1999).
   PubMed Web of Science ®Google Scholar
• Doval HC, Nul DR, Grancelli HO et al.; Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet344, 493–498 (1994).
   PubMed Web of Science ®Google Scholar
• Singh SN, Fletcher RD, Fisher SG et al. The survival trial of antiarrhythmic therapy in congestive heart failure. N. Engl. J. Med.333, 77–82 (1995).
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med.352, 225–237 (2005).
   PubMed Web of Science ®Google Scholar
• Køber L, Torp-Pedersen C, McMurray JJV et al.; Dronedarone Study Group. Increased Mortality after Dronedarone Therapy for Severe Heart Failure. N. Engl. J. Med.358, 2678–2687 (2008).
   PubMed Web of Science ®Google Scholar
• Roy D, Talajic M, Nattel S et al.; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med.358(25), 2667–2677 (2008).
   PubMed Web of Science ®Google Scholar
• Khan MN, Jaïs P, Cummings J et al.; PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N. Engl. J. Med.359(17), 1778–1785 (2008).
   PubMed Web of Science ®Google Scholar
• Moss AJ, Hall WJ, Cannom DS et al.; Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N. Engl. J. Med.335, 1933–1940 (1996).
   PubMed Web of Science ®Google Scholar
• Buxton AE, Lee KL, Fisher JD et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N. Engl. J. Med.341, 1882–1890 (1999).
   PubMed Web of Science ®Google Scholar
• Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med.346, 877–878 (2002).
   PubMed Web of Science ®Google Scholar
• Gold MR, Ip JH, Costantini O et al. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction. Circulation118, 2022–2028 (2008).
   PubMed Web of Science ®Google Scholar
• Bristow MR, Saxson LA, Boehmer J et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med.350, 2140–2150 (2004).
   PubMed Web of Science ®Google Scholar
• Kantharia BK. Cost–effectiveness aspects of defibrillators: decreasing the financial burden. Cardiol. Manage.3(1), 13–14 (2009).
   Google Scholar